Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 167

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 167
---
     |                  | — |
| Michael Zinda, Ph.D.       |     |              | 31,516 |     |                  | 57,359 |     |                  | 160,000 |     |                 | 104,000 |     |                  | — |

| (4) | The amounts in this column represent the estimated value of post-termination benefits coverage for 12 months.                                                                                                                    
 The amounts in this column are considered “double-trigger” as they will only be payable in the event of a qualifying termination of employment following the closing. Because Mr. Segal and Dr. Koehler were terminated prior to 
 the Arrangement, neither will receive post termination benefit coverage in connection with the Arrangement.                                                                                                                      |

Canadian Securities Law Matters The Company is a reporting issuer in Québec, and, accordingly, is subject to MI 61-101.MI 61-101is intended to regulate certain transactions to ensure equality of treatment among security holders, generally requiring enhanced disclosure, approval by a majority of security holders excluding “interested parties” or “related parties” (as such terms are defined in MI 61-101)and/or, in certain instances, independent valuations and approval and oversight of the transaction by a transaction committee of independent directors. The protections of MI 61-101generally apply to “business combinations” (as defined in MI 61-101)that terminate the interests of security holders without their consent. MI 61-101provides that, in certain circumstances where a “related party” (as defined in MI 61-101)of an issuer is entitled to receive a “collateral benefit” (as defined in MI 61-101)in connection with an arrangement transaction (such as the Arrangement), such transaction may be considered a “business combination” for the purposes of MI 61-101and subject to minority approval requirements. A “collateral benefit,” as defined in MI 61-101,includes any benefit that a “related party” of the Company (which includes the directors and senior officers of the Company) is entitled to receive, directly or indirectly, as a consequence of the Arrangement, including, without limitation, an increase in salary, a lump sum payment, a payment for surrendering securities or other enhancement in benefits related to past or future services as an employee, director or consultant of the Company, regardless of the existence of any offsetting costs to the related party or whether the benefit is provided, or agreed to, by the Company,